GenSpera, Inc. is a biotechnology company focused on the development and commercialization of promising, new therapeutics. Our work is motivated by a commitment to innovation and helping patients. We combine our powerful insights and rigorous scientific methods to create new treatment options for patients.

  • Mipsagargin, our lead agent, is in human clinical trials for patients with several different tumor types:
    • Hepatocellular carcinoma, or liver cancer
    • Glioblastoma, or brain cancer
    • Prostate cancer
  • Our experienced and motivated team has deep pharmaceutical industry and scientific experience:
    • Both the management team and board of directors have extensive experience in bringing new treatments from discovery to development.
    • The scientific team includes leading researchers at Johns Hopkins and the University of Copenhagen
  • Our cutting-edge platform technology has the potential to work across a spectrum of drugs that precisely target different cancers.
  • We are boldly pursuing the opportunities found within our research, expanding our technology platform to design treatments for other clinical indications.
  • GenSpera has a strong intellectual property portfolio and has been granted orphan drug status by the U.S. Food and Drug Administration for its lead agent.